In This Section


Monday, October 19, 2020

Tuesday, October 20, 2020


Welcome and Introduction by Marcela V. Maus, Massachusetts General Hospital, Boston, Massachusetts
10-11:20 A.M.

Clinical development of BCMA-directed therapies in multiple myeloma
Kristen M. Hege, Celgene Corporation, San Francisco, California
(Not eligible for CME credit)

A case for priming, not checkpoint
Robert H. Vonderheide, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

11:20-11:35 A.M.
Plenary Session 1: Synthetic Biology and Novel Approaches to Immune Engineering
Session Chair: Jonathan P. Schneck, Johns Hopkins University School of Medicine, Baltimore, Maryland
11:35 A.M.-12:50 P.M.

Engineering artificial antigen presenting cells, aAPC, for cancer immunotherapy: From bench to bedside
Jonathan P. Schneck

Cancer stem cells as origin of tumor associated immune cells*
Ghmkin Hassan, Okayama University, Okayama, Japan

Highly parallel knock-in targeting for genome engineering of cellular therapies*
Theodore Roth, University of California San Francisco, San Francisco, California

Single-cell profiling of acute myeloid leukemia (AML) and its microenvironment reveals a CD8 continuum and adaptable T cell plasticity in response to PD-1 blockade-based therapy*
Hussein Abbas, MD Anderson Cancer Center, Houston, Texas

12:50-1:05 P.M.
Plenary Session 2: Innate and Adaptive Checkpoints
Session chair: Timothy A. Chan, Cleveland Clinic, Cleveland, Ohio
1:05-2:35 P.M.      

Targeting macrophages to promote anti-tumor immunity
Judith A. Varner, UCSD Moores Cancer Center, San Diego, California

Innate immune defenses against cancer: Potential for mobilizing NK cells for cancer immunotherapy
David H. Raulet, University of California Berkeley, Berkeley, California

Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation*
Bogang Wu, The George Washington University, Washington, DC

Highly potent fully human anti-VISTA antibodies – A new target checkpoint inhibitor against immunosuppressive myeloid cells*
Thierry Guillaudeux, Kineta Inc., Seattle, Washington

2:35-2:50 P.M.
Plenary Session 3: Novel Combinations
Session Chair: Charles G. Drake, Columbia University Irving Medical Center, New York, New York
2:50-4:50 P.M.

Combination immunotherapy targeting myeloid populations
Charles G. Drake

The QuEST for an effective immunotherapy for prostate cancer
James L. Gulley, National Cancer Institute, Bethesda, Maryland

What are some different ways to evaluate immunotherapy combinations?
Michael Postow, Memorial Sloan Kettering Cancer Center, New York, New York

27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression*
Liqian Ma, University of Illinois Urbana-Champaign, Urbana, Illinois

Is sex an effect modifier for cancer immune checkpoint inhibitors? – A population-based study*
Se Ryeong Jang, Thomas Jefferson University, Philadelphia, Pennsylvania


Day 2 Keynote Presentation
10-10:40 A.M.

The IRE1 ER stress sensor activates natural killer cell immunity by regulating c-Myc
Laurie H. Glimcher, Dana-Farber Cancer Institute, Boston, Massachusetts

10:40-10:55 A.M.
Plenary Session 4: Vaccines, Neoantigens, and Oncolytic Viruses
Session Chair: Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts
10:55 A.M.-12:25 P.M.

Building improved personal cancer vaccines
Catherine J. Wu

Viral vectored vaccines for prostate cancer
Adrian V.S. Hill, Jenner Institute at Oxford University, Oxford, England

Armed Myxoma virus demonstrates therapeutic activity alone and in combination with immune checkpoint inhibitors in pre-clinical models*
Leslie Sharp, OncoMyx Therapeutics, Phoenix, Arizona
(Not eligible for CME credit)

The functional genomic landscape of recurrent glioblastoma*
Sheila Singh, McMaster University, Hamilton, Ontario

12:25-12:40 P.M.
Plenary Session 5: Non-T-Cell Therapies
Session chair: Marcela V. Maus, Massachusetts General Hospital, Boston, Massachusetts
12:40-2:10 P.M.

Informing therapy by elucidating natural mechanisms of tissue immunosurveillance
Adrian C. Hayday, The Francis Crick Institute, London, England

The future of CAR therapies
Elizabeth J. Shpall, The University of Texas MD Anderson Cancer Center, Houston, Texas

Potentiating the efficacy of immune checkpoint blockade by targeting the epithelial-to-mesenchymal transition (EMT) in breast carcinomas*
Anushka Dongre, Whitehead Institute for Biomedical Research, Cambridge, Massachusetts

Selective inhibition of VEGF binding to VEGFR2 promotes an immune stimulatory microenvironment in murine models of breast cancer*
Yuqing Zhang, University of Texas Southwestern Medical Center, Dallas, Texas

2:10-2:25 P.M.
Plenary Session 6: T-Cell Therapies
Session chair: Marcela V. Maus, Massachusetts General Hospital, Boston, Massachusetts
2:25-3:55 P.M.

The sweet side of CAR-T cells: Reprogramming T cells to target glycopeptide epitopes
Avery D. Posey, University of Pennsylvania, Philadelphia, Pennsylvania

Next generation CAR T cells for cancer therapy
Renier J. Brentjens, Memorial Sloan Kettering Cancer Center, New York, New York

Adoptive transfer of T cells surface-tethered with IL-12 activates a natural killer/dendritic cell axis to promote antigen spreading for enhanced anti-tumor efficacy *
Kate Stokes, Repertoire Immune Medicines, Cambridge, Massachusetts

Microfluidic purification of T lymphocytes separated from blood for chimeric antigen receptor T-cell manufacturing*
Mona Elsemary, University of South Australia, Mawson Lakes, Australia

3:55-4:10 P.M.
Plenary Session 7: Defining Novel Immunotherapy Targets
Session Chair and Closing Remarks: Arlene H. Sharpe, Harvard Medical School, Boston, Massachusetts
4:10-5:40 P.M.

Discovery of new immunotherapy targets and mechanisms leveraging CRISPR
Arlene H. Sharpe

The role of the senescence-associated secretory phenotype  in cancer
Stephen J. Elledge, Harvard Medical School, Boston, Massachusetts

A novel immunotherapy for relapsed/refractory pediatric T-cell acute lymphoblastic leukemia*
Christopher Foley, Allterum Therapeutics, Inc. and Fannin Innovation Studio, Houston, Texas
(Not eligible for CME credit)

IL33 cytokine signalling in gastrointestinal cancers – a therapy target?*
Moritz Eissmann, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia

Closing Remarks
5:40 p.m.

*Short talk from proffered abstract